CTNNB1 and endometrial carcinoma: In contrast, strong nuclear β-catenin localization, typically associated with overall overexpression, serves as a reliable indicator of β-catenin activation in AH/EIN or endometrial carcinoma, demonstrating ≥90% specificity and sensitivity for CTNNB1 mutations [63,64,65].